LUNIVIA

This brand name is authorized in Germany

Active ingredients

The drug LUNIVIA contains one active pharmaceutical ingredient (API):

1 Eszopiclone
UNII UZX80K71OE - ESZOPICLONE

Eszopiclone is indicated for the treatment of insomnia. The mechanism of action of eszopiclone as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.

Read about Eszopiclone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N05CF04 Eszopiclone N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CF Benzodiazepine related drugs
Discover more medicines within N05CF04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: DE Bundesinstitut fĂźr Arzneimittel und Medizinprodukte Identifier(s): 16626948, 16626954, 16626960, 16626983, 16627008, 16627014, 16627037, 16627043, 16627066

Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈